<DOC>
	<DOCNO>NCT02828098</DOCNO>
	<brief_summary>12 24 patient aggressive solid tumor biopsy obtain , receive BO-112 IT administration . Injected lesion must palpable biopsiable time injection , biopsied 7-14 day . Patients receive alternative therapy period comprise first second biopsy . BO-112 administer start dose . Upon confirmation safety profile start dose evaluation pharmacokinetic ( PK ) profile , three additional dose level expect tested . During course study , subject examine side effect may occur ( safety tolerability ) . Additionally study also study BO-112 biological activity , innate adaptive immune system response signal pathway , well sign clinical relevance , study .</brief_summary>
	<brief_title>Exploratory Study BO-112 Adult Patients With Aggressive Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Aggression</mesh_term>
	<criteria>1 . Patients age 18 year day signing inform consent form . 2 . Histologically cytologically confirm aggressive solid tumor 3 . Patients must : Biopsyaccessible tumor No prior anticancer treatment last 14 day Other relevant clinically significant concomitant disease adverse clinical condition may jeopardize patient safety : Increased cardiac risk : congestive heart failure ; unstable angina pectoris ; arrhythmia require treatment uncontrolled arterial hypertension ; myocardial infarction within 12 month inclusion study . Patients active central nervous system ( CNS ) lesion ( include carcinomatous meningitis ) exclude . However , patient eligible : All know CNS lesion treat stereotactic therapy surgery , AND There evidence clinical radiographic disease progression CNS â‰¥ 4 week radiotherapy surgery , require increase last 4 week steroid use start new course steroid Whole brain radiotherapy allow , exception patient definitive resection stereotactic therapy radiologically detectable parenchymal brain lesion . Active infection . Significant nonneoplastic liver disease ( e.g. , cirrhosis , active chronic hepatitis B C ) . Any clinically significant abnormality history examination include diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study medication ( physiologic dos corticosteroid may approve consultation Sponsor ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>aggressive solid tumor</keyword>
</DOC>